Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies Late-breaking presentation…
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (Article 223-16 of the General Regulations of the Autorité…
Doré Copper et Cygnus Metals concluent une entente d’arrangement afin de créer une société de minéraux critiques stratégique
Ne pas distribuer aux services de fil de presse des États-Unis ni diffuser aux États-Unis TORONTO, 15 oct. 2024 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (« Doré Copper »)…
Top Wealth Group Holding Limited Announces Closing of $10.8 Million Public Offering of Ordinary Shares
Hong Kong, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Top Wealth Group Holding Limited (NASDAQ: TWG) (“Top Wealth” or the “Company”), a Hong Kong-based supplier of luxury caviar products, today announced…
LLYC’s operating revenue grows 12% in the first half of 2024, reaching 43.2 million euros
Audited results The acquisition of Lambert by LLYC in the U.S. drives business growthEffective expense management has led to an EBITDA margin of 16%The firm concludes a record-breaking semester in…
Bel Announces Appointment of Umasankar (‘Uma”) Pingali as Global Head of Sales and Marketing
WEST ORANGE, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bel Fuse Inc. (“Bel,” or, “the Company”) (Nasdaq:BELFA and Nasdaq:BELFB), today announced its appointment of Uma Pingali as Global Head of…
Ardena élargit sa présence aux États-Unis avec l’acquisition d’une unité de production pharmaceutique du réseau Catalent
Gand, Belgique, 14 oct. 2024 (GLOBE NEWSWIRE) -- Ardena, un sous-traitant pharmaceutique (ou CDMO pour Contract Development and Manufacturing Organisation) spécialisé dans le développement de nouveaux traitements thérapeutiques, avec des…
Form 8.3 – [KEYWORDS STUDIOS PLC – 11 10 2024]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS…
Form 8.3 – [ECKOH PLC – 11 10 2024]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…